ViewRay Stock

ViewRay Debt

The Debt of ViewRay (VRAYQ) as of Sep 4, 2026 is 78.30 M USD. In the previous year, Debt was 57.30 M USD — a change of 36.65% (higher).

Debt

78.30 MUSD

YoY

36.65%

Last updated:

In 2026, ViewRay's total debt was 78.30 M USD, a 36.65% change from the 57.30 M USD total debt recorded in the previous year.

The ViewRay Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2015
29.00 M USD
Jan 1, 2016
44.30 M USD
Jan 1, 2017
44.50 M USD
Jan 1, 2018
55.40 M USD
Jan 1, 2019
55.60 M USD
Jan 1, 2020
56.90 M USD
Jan 1, 2021
57.30 M USD
Jan 1, 2022
78.30 M USD
The ViewRay Debt history
YEARDebtYoY
78.30 MUSD+36.65%
57.30 MUSD+0.70%
56.90 MUSD+2.34%
55.60 MUSD+0.36%
55.40 MUSD+24.49%
44.50 MUSD+0.45%
44.30 MUSD+52.76%
29.00 MUSD+93.33%
15.00 MUSD
Access this data via the Eulerpool API

ViewRay Stock analysis

What does ViewRay do? ViewRay Inc. is an American medical technology company based in Cleveland, Ohio. It was founded in 2004 by Ivor Jankovic and specializes in the manufacturing of radiation therapy devices. The history of ViewRay begins with the idea of developing innovative technology to treat cancer patients more effectively and gently. In 2005, the company entered into an agreement with the Cleveland Clinic Lerner Research Institute to conduct research on a novel magnetic resonance-guided radiation therapy machine. The research project was led by James F. Dempsey, Chair of the Department of Radiation Oncology at the Cleveland Clinic. In 2009, the first magnetic resonance-guided radiation therapy system was delivered and implemented at the Cleveland Clinic. ViewRay's business model is based on the development and manufacturing of innovative medical devices aimed at making the treatment of cancer patients more effective and gentle. The company focuses on combining magnetic resonance imaging (MRI) and radiation therapy to ensure more precise and safer treatment. ViewRay offers various products, including the MRIdian-Linac system, an advanced radiation therapy device that utilizes MRI technology to provide real-time images of the tumor during radiation. This allows for precise targeting of the tumor while sparing the surrounding tissue. The system also offers the ability to sync radiation therapy with the patient's breathing cycle, further improving the accuracy and effectiveness of the treatment. In addition to the MRIdian-Linac system, ViewRay also offers the MRIdian-MRI system, which is solely dedicated to imaging. The MRIdian-MRI is a diagnostic instrument that allows for better visualization of tissue and tumor studies. The system uses the same MRI technology as the MRIdian-Linac to generate radiation-free images. ViewRay has also specialized in the development of software tools that assist doctors in better planning and monitoring radiation therapy. This includes the RayCare Oncology Information System, which provides a comprehensive workflow and management platform, as well as the RayStation Treatment Planning Software, which enables more precise radiation therapy planning. In terms of market reach, ViewRay has a global presence. The company has a strong presence in North America, Europe, and Asia, and works closely with leading research institutes and hospitals to evaluate and improve the effectiveness and efficiency of its technologies. Overall, ViewRay has developed an innovative and unique portfolio of products and solutions that improve radiation therapy and increase accuracy and safety for patients and doctors. The company is a leader in the development of MRI-guided radiation therapy systems and is expected to continue playing a significant role in the medical technology industry in the future. ViewRay is one of the most popular companies on Eulerpool.

Debt Details

Understanding ViewRay's Debt Structure

ViewRay's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing ViewRay's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to ViewRay’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in ViewRay’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about ViewRay stock

Debt of ViewRay is 78.30 M USD in 2026.

Debt of ViewRay changed from 57.30 M USD to 78.30 M USD, representing a 36.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt ViewRay since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's ViewRay historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — ViewRay

All Key Metrics — ViewRay